Author(s)

Suming Jie^*, Jinmei Deng^*, Caixia Lin, Xiuzhen Cai, Dongmei Cai

Outpatient Clinic of Internal Medicine Department, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou China.

Objective: To explore the clinical efficacy of Zoledronic Acid Injection in the treatment of postmenopausal osteoporosis with different bone turnover rates. Methods: A total of 63 patients diagnosed with postmenopausal osteoporosis were included in this study. Each patient was administrated 5 mg/100mL Zoledronic Acid (Aclasta) intravenously once and then given a one-year prescription of 600 mg/d oral Caltrate. The bone turnover parameters (PINP, β-cross, N-MID) were measured prior to the injection of Zoledronic Acid while the bone mineral density (BMD) and the pain scores of each patient were tested before treatment and after the one-year medication. On this basis, the patients were divided into several groups according to their bone turnover rates for intergroup comparison of treatment outcomes. Results: BMD results and pain scores of all participants were significantly improved at different levels after treatment. However, these improvements had no significant differences between the patients with high and low bone turnover rates. Conclusion: Zoledronic Acid Injection can relieve bone pain, enhance the quality of life and increase the BMD in patients with postmenopausal osteoporosis, regardless of the bone turnover status.

Osteoporosis, Postmenopausal, Bone Turnover Rate, Zoledronic Acid

Jie, S. , Deng, J. , Lin, C. , Cai, X. and Cai, D. (2018) Curative Effect Analysis of Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis with Different Bone Turnover Rates. International Journal of Clinical Medicine, 9, 621-628. doi: 10.4236/ijcm.2018.98052.